Journal
GASTROENTEROLOGY
Volume 156, Issue 2, Pages 311-324Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2018.07.057
Keywords
Functional Cure; Direct-acting Antivirals; Drug; Screening
Categories
Funding
- Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States
- ILCA-Bayer fellowship
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054503] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Hepatitis B virus (HBV) infection affects approximately 300 million people worldwide. Although antiviral therapies have improved the long-term outcomes, patients often require life-long treatment and there is no cure for HBV infection. New technologies can help us learn more about the pathogenesis of HBV infection and develop therapeutic agents to reduce its burden. We review recent advances in development of direct-acting antiviral and host-targeting agents, some of which have entered clinical trials. We also discuss strategies for unbiased high-throughput screens to identify compounds that inhibit HBV and for repurposing existing drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available